Quick Answer
Definium Therapeutics, Inc. reported Net Income of -$183.79 million for fiscal year 2025.
Definium Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$183.79M -69.1% |
-$108.68M -13.5% |
-$95.73M -68.6% |
-$56.80M +39.0% |
-$93.04M -174.1% |
-$33.94M |
| Diluted EPS | -$2.06 -33.8% |
-$1.54 +36.9% |
-$2.44 -32.6% |
-$1.84 +45.9% |
-$3.40 | — |
| Total Assets | $440.10M +45.7% |
$302.15M +142.6% |
$124.54M -26.7% |
$169.99M +3.7% |
$164.00M +101.2% |
$81.52M |
| Cash and Equivalents | $257.84M -5.8% |
$273.74M +174.6% |
$99.70M -29.9% |
$142.14M +6.4% |
$133.54M +66.7% |
$80.09M |
| Stockholders Equity | $332.33M +37.6% |
$241.45M +209.0% |
$78.13M -48.2% |
$150.92M -0.5% |
$151.66M +99.9% |
$75.87M |
| R&D Expense | $117.67M +80.2% |
$65.30M +25.3% |
$52.12M +44.1% |
$36.17M +4.0% |
$34.79M +86.7% |
$18.63M |
| Operating Income | -$166.31M -60.0% |
-$103.92M -10.7% |
-$93.87M -41.5% |
-$66.33M +29.3% |
-$93.85M -184.1% |
-$33.03M |
| Shares Outstanding | 98.78M +31.5% |
75.10M +82.7% |
41.10M +8.2% |
37.98M +35.0% |
28.13M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$67.27M | -391.6% | -57.4% |
| Diluted EPS | September 30, 2025 | -$0.78 | -188.9% | -56.0% |
| Total Assets | September 30, 2025 | $236.92M | -25.9% | -10.6% |
| Cash and Equivalents | September 30, 2025 | $19.96M | -93.2% | -40.2% |
| Stockholders Equity | September 30, 2025 | $130.60M | -50.2% | -29.6% |
| R&D Expense | September 30, 2025 | $30.98M | +80.2% | +3.9% |
| Operating Income | September 30, 2025 | -$45.67M | -84.2% | -11.7% |
| Shares Outstanding | September 30, 2025 | 76.77M | -5.9% | +1.3% |
- Definium Therapeutics, Inc. reported Net Income of -$183.79 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed a decrease of -69.1% in Net Income compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Diluted EPS of $2.06 per share (loss) for fiscal year 2025.
- Definium Therapeutics, Inc. showed a decrease of -33.8% in Diluted EPS compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Total Assets of $440.10 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed an increase of +45.7% in Total Assets compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Cash and Equivalents of $257.84 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed a decrease of -5.8% in Cash and Equivalents compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Stockholders Equity of $332.33 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed an increase of +37.6% in Stockholders Equity compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported R&D Expense of $117.67 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed an increase of +80.2% in R&D Expense compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Operating Income of -$166.31 million for fiscal year 2025.
- Definium Therapeutics, Inc. showed a decrease of -60.0% in Operating Income compared to the prior fiscal year.
- Definium Therapeutics, Inc. reported Shares Outstanding of 98.78 million shares for fiscal year 2025.
- Definium Therapeutics, Inc. showed an increase of +31.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: